Xenetic Biosciences
XBIO | NASDAQ
$1.49
-$0.17 (-10.24%)
At close: Nov 16, 2026, 4:00 PM ET
$1.60
+$0.11 (+7.72%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Xenetic Biosciences Company Profile
Company profile explainedCompany Profile
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | 8-K | Current Report |
| Sep 18, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 16, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| May 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| May 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 13, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 24, 2026 | 10-K/A | [Amend] Annual Report |
Xenetic Biosciences
| Country | United States |
| IPO Date | Jun 30, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | James F. Parslow |
Contact Details
945 Concord Street Framingham,
Massachusetts 01701 United States
Stock Details
| Ticker Symbol | XBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534525 |
| CUSIP Number | 984015602 |
| ISIN Number | US9840156023 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove XBIO